ArticleStem cells international2010
Stem cell-based therapies for liver diseases: state of the art and new perspectives.
Article in Stem cells international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 60 citations in OpenAlex.
- Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis.The Korean journal of internal medicine · 2017Trial
- The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency.Stem cell research & therapy · 2015Trial
- Review
- Therapeutic potential of exosome derived from hepatocyte growth factor-overexpressing adipose mesenchymal stem cells in TGFβ1-stimulated hepatic stellate cells.Cytotechnology · 2024Article
- Repeated Autologous Bone Marrow Transfusion through Portal Vein for Treating Decompensated Liver Cirrhosis after Splenectomy.Gastroenterology research and practice · 2018Article
- A Convenient and Efficient Method to Enrich and Maintain Highly Proliferative Human Fetal Liver Stem Cells.Rejuvenation research · 2015Article
- Bone marrow derived stem cells for the treatment of end-stage liver disease.World journal of gastroenterology · 2014Review
- Combined use of N-acetylcysteine and Liberase improves the viability and metabolic function of human hepatocytes isolated from human liver.Cytotherapy · 2014Article
- Therapeutic potential of mesenchymal stem cells overexpressing human forkhead box A2 gene in the regeneration of damaged liver tissues.Journal of gastroenterology and hepatology · 2012Article
- Model systems and clinical applications of hepatic stem cells for liver regeneration.Hepatology international · 2012Article
- Meeting the need for regenerative therapies I: target-based incidence and its relationship to U.S. spending, productivity, and innovation.Tissue engineering. Part B, Reviews · 2012Article
- Cell therapies for liver diseases.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2012Review
- Induced pluripotent stem cells and personalized medicine: current progress and future perspectives.Anatomy & cell biology · 2011Article
- Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling.Journal of experimental & clinical cancer research : CR · 2011Article
- Review
- Potential applications of germline cell-derived pluripotent stem cells in organ regeneration.OrganogenesisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Millions of patients worldwide suffer from end-stage liver pathologies, whose only curative therapy is liver transplantation (OLT). Given the donor organ shortage, alternatives to OLT have been evaluated, including cell therapies. Hepatocyte transplantation has been attempted to cure metabolic liver disorders and end-stage liver diseases. The evaluation of its efficacy is complicated by the shortage of human hepatocytes and their difficult expansion and cryopreservation. Recent advances in cell biology have led to the concept of "regenerative medicine", based on the therapeutic potential of stem cells (SCs). Different types of SCs are theoretically eligible for liver cell replacement. These include embryonic and fetal SCs, induced pluripotent cells, annex SCs, endogenous liver SCs, and extrahepatic adult SCs. Aim of this paper is to critically analyze the possible sources of SCs suitable for liver repopulation and the results of the clinical trials that have been published until now.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.